Muse® Launches Advanced Cognitive Performance Metric

TORONTO--(BUSINESS WIRE)--Muse® by Interaxon, a leader in brain health and neurotechnology, proudly announces the launch of a new cognitive performance metric, Alpha Peak. As the first in a suite of advanced brain health metrics, Alpha Peak empowers users to enhance cognitive performance through personalized, actionable insights with an easy-to-understand score—paving the way for enhanced mental fitness.

“This research has the potential to revolutionize early intervention strategies, offering new hope for those at risk of cognitive decline.”

As we age, cognitive decline becomes an increasingly significant concern with no convenient way to measure it. Research indicates that certain cognitive functions, including memory, executive functions, processing speed, and reasoning, begin to decline from as early as the 30s1. Furthermore, studies suggest that mild cognitive impairment (MCI) affects 10-20% of adults over 65, with the potential to evolve into more severe cognitive issues if left unmanaged2.

Introducing Alpha Peak: The HRV of the Brain

Similar to how heart rate variability (HRV) provides insights into cardiovascular health, Alpha Peak can help you understand your brain’s aging process and take charge of your cognitive health. Research indicates that alpha peak frequency (APF) varies with age: it increases during childhood, peaking in early adulthood, and declining thereafter. This pattern suggests APF is closely tied to cognitive maturation and aging. A 2016 foundational study involving over 6,000 participants using Muse devices found a strong correlation between APF and cognitive performance, including overall cognitive health, processing speed, and memory3.

By leveraging Muse mEEG devices to measure individual APF after biofeedback sessions, users can obtain a cognitive performance score with personalized tips for optimizing alpha wave activity. After completing a few Muse sessions, a personalized baseline is established, and users will receive a graph showing whether their Alpha Peak falls within, below, or above this baseline.

As users monitor lifestyle factors such as diet, exercise, and sleep, they can directly correlate these changes with their Alpha Peak score and receive personalized prompts to optimize their habits accordingly.

“Muse has strategically positioned itself at the forefront of brain health by focusing on key areas such as enhancing focused attention, revolutionizing at-home sleep support, and now with Alpha Peak, advancing cognitive performance,” said Jean-Michel Fournier, CEO of Muse. “Each of these initiatives aligns with our audacious goal of improving brain health globally, through accessible advanced neurotechnology.”

Advancing Brain Health with Innovative Research

Muse’s commitment to brain health goes beyond cognitive performance, driving research across multiple critical areas such as sleep and cognitive decline:

AI-Powered Sleep Diagnostics & Therapeutics: Muse’s mEEG headbands, equipped with advanced sleep staging algorithms, offer unmatched precision and scalability compared to traditional diagnostic methods. Advanced sleep analysis is now more accessible to researchers and clinicians worldwide, pushing the boundaries beyond traditional sleep staging with macro and micro architecture insights.

Formative research with esteemed partners in the fields of depression, insomnia, and PTSD explores novel sleep interventions with Muse devices and the intricate relationships between sleep and these conditions, working towards creating strategies that could significantly enhance the quality of life for those affected.
 

Brain Age & Cognitive Decline: Last year, Muse published research with over 5,000 participants on the effects of aging on brain function, leading to the development of a “Brain Age Score”4. A breakthrough metric that would allow users to track the health and age of their brain relative to their chronological age, providing actionable insights for maintaining and improving cognitive health over time.

In 2024, a large-scale study focused on mild cognitive decline (MCI) will be conducted in partnership with principal investigator Dr. Olav Krigolson from the University of Victoria, aiming to improve MCI diagnosis and tracking using Muse devices for at-home brain measurements.

“The ability to measure brain health in real-time with Muse’s technology is a game-changer for diagnosing and managing mild cognitive impairment,” said Dr. Olav Krigolson PhD, professor and principal investigator of the study. “This research has the potential to revolutionize early intervention strategies, offering new hope for those at risk of cognitive decline.”

About Muse by Interaxon Inc

Muse is pioneering brain health through its industry-leading mEEG platform, built on advanced AI algorithms. Muse spearheads decentralized research initiatives focused on enhancing mental health, optimizing sleep, and advancing cognitive performance through innovative neurotechnology. Muse’s AI-driven neurotech tools empower researchers, developers, and consumers worldwide, and is underpinned by over 200 third-party-led research studies from renowned institutions including the Mayo Clinic, MIT, and Harvard. Muse has collected and decoded over 1 billion minutes of brain data to-date, comprising one of the largest EEG collections in the world. Muse is headquartered in Toronto, Canada.